IL106142A - Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them - Google Patents

Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them

Info

Publication number: IL106142A
Authority: IL; Israel
Prior art keywords: optionally substituted; phenyl; alkyl; group; substituent
Prior art date: 1992-06-29

Application number

IL106142A

Other languages

English (en)

Other versions

IL106142A0 (en

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-29

Filing date

1993-06-25

Publication date

1997-03-18

1993-06-25 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1993-10-20 Publication of IL106142A0 publication Critical patent/IL106142A0/xx

1997-03-18 Publication of IL106142A publication Critical patent/IL106142A/xx

Links

239000002462 tachykinin receptor antagonist Substances 0.000 title abstract 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title 2
239000008194 pharmaceutical composition Substances 0.000 title 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 title 1
125000001424 substituent group Chemical group 0.000 abstract 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 9
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
125000000623 heterocyclic group Chemical group 0.000 abstract 7
229910052739 hydrogen Inorganic materials 0.000 abstract 6
239000001257 hydrogen Substances 0.000 abstract 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 5
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
125000001475 halogen functional group Chemical group 0.000 abstract 3
125000002883 imidazolyl group Chemical group 0.000 abstract 3
125000002971 oxazolyl group Chemical group 0.000 abstract 3
125000003386 piperidinyl group Chemical group 0.000 abstract 3
125000004076 pyridyl group Chemical group 0.000 abstract 3
125000000719 pyrrolidinyl group Chemical group 0.000 abstract 3
125000000168 pyrrolyl group Chemical group 0.000 abstract 3
125000000335 thiazolyl group Chemical group 0.000 abstract 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000002837 carbocyclic group Chemical group 0.000 abstract 2
125000002541 furyl group Chemical group 0.000 abstract 2
125000001544 thienyl group Chemical group 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
125000005940 1,4-dioxanyl group Chemical group 0.000 abstract 1
206010002383 Angina Pectoris Diseases 0.000 abstract 1
229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
101100134929 Gallus gallus COR9 gene Proteins 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
206010065390 Inflammatory pain Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
125000002393 azetidinyl group Chemical group 0.000 abstract 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
239000000480 calcium channel blocker Substances 0.000 abstract 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000001041 indolyl group Chemical group 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
-1 isooxazolyl Chemical group 0.000 abstract 1
125000001786 isothiazolyl group Chemical group 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
125000004193 piperazinyl group Chemical group 0.000 abstract 1
125000003373 pyrazinyl group Chemical group 0.000 abstract 1
125000003226 pyrazolyl group Chemical group 0.000 abstract 1
125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
125000005493 quinolyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
125000005958 tetrahydrothienyl group Chemical group 0.000 abstract 1
125000003831 tetrazolyl group Chemical group 0.000 abstract 1
125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
125000001425 triazolyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL106142A 1992-06-29 1993-06-25 Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them IL106142A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US90597692A	1992-06-29	1992-06-29
US97144892A	1992-11-04	1992-11-04
US6191493A	1993-05-19	1993-05-19

Publications (2)

Publication Number	Publication Date
IL106142A0 IL106142A0 (en)	1993-10-20
IL106142A true IL106142A (en)	1997-03-18

Family

ID=27370159

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL106142A IL106142A (en)	1992-06-29	1993-06-25	Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them

Country Status (33)

Country	Link
EP (1)	EP0577394B1 (de)
JP (1)	JP2634372B2 (de)
KR (1)	KR100301212B1 (de)
CN (1)	CN1049431C (de)
AT (1)	ATE186532T1 (de)
AU (1)	AU4656193A (de)
BG (1)	BG62963B1 (de)
BR (1)	BR1100375A (de)
CA (1)	CA2099233A1 (de)
CY (1)	CY2200B1 (de)
CZ (1)	CZ288530B6 (de)
DE (1)	DE69326977T2 (de)
DK (1)	DK0577394T3 (de)
DZ (1)	DZ1700A1 (de)
ES (1)	ES2141133T3 (de)
FI (1)	FI111363B (de)
GR (1)	GR3031824T3 (de)
HR (1)	HRP931003B1 (de)
HU (1)	HU219713B (de)
IL (1)	IL106142A (de)
LV (1)	LV12568B (de)
MX (1)	MX9303888A (de)
MY (1)	MY108836A (de)
NO (1)	NO305698B1 (de)
NZ (1)	NZ254476A (de)
RO (1)	RO114448B1 (de)
RU (1)	RU2140914C1 (de)
SI (1)	SI9300346B (de)
SK (1)	SK281093B6 (de)
TW (1)	TW358808B (de)
WO (1)	WO1994000440A1 (de)
YU (1)	YU49036B (de)
ZA (1)	ZA934624B (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6048859A (en)	1992-06-29	2000-04-11	Merck & Co., Inc.	Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) *	1992-06-29	1997-06-10	Merck & Co., Inc.	Process for preparing morpholine tachykinin receptor antagonists
US5719147A (en) *	1992-06-29	1998-02-17	Merck & Co., Inc.	Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) *	1993-12-17	1999-12-22	Merck & Co Inc	Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) *	1993-12-29	2005-03-22	Raymond Baker	Substituted morpholine derivatives and their use as therapeutic agents
US5610165A (en) *	1994-02-17	1997-03-11	Merck & Co., Inc.	N-acylpiperidine tachykinin antagonists
IL112778A0 (en) *	1994-03-04	1995-05-26	Merck & Co Inc	Substituted heterocycles, their preparation and pharmaceutical compositions containing them
JPH10500944A (ja) *	1994-05-05	1998-01-27	メルクシヤープエンドドームリミテツド	モルホリン誘導体及びタキキニンのアンタゴニストとしてのそれらの使用
WO1996005181A1 (en) *	1994-08-15	1996-02-22	Merck Sharp & Dohme Limited	Morpholine derivatives and their use as therapeutic agents
GB9417956D0 (en) *	1994-09-02	1994-10-26	Merck Sharp & Dohme	Therapeutic agents
US5457107A (en) *	1994-09-16	1995-10-10	Merck & Co., Inc.	Polymorphic form of a tachykinin receptor antagonist
FR2728165A1 (fr) *	1994-12-19	1996-06-21	Oreal	Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
GB9426102D0 (en) *	1994-12-23	1995-02-22	Merck Sharp & Dohme	Pharmacuetical compositions
GB9426103D0 (en) *	1994-12-23	1995-02-22	Merck Sharp & Dohme	Therapeutic agents
FR2729954B1 (fr) *	1995-01-30	1997-08-01	Sanofi Sa	Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
DE19504627A1 (de) *	1995-02-13	1996-08-14	Bayer Ag	Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen
GB9505491D0 (en) *	1995-03-18	1995-05-03	Merck Sharp & Dohme	Therapeutic agents
GB9505492D0 (en) *	1995-03-18	1995-05-03	Merck Sharp & Dohme	Therapeutic agents
JP3053222B2 (ja) *	1995-04-20	2000-06-19	ファイザー・インコーポレーテッド	Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
GB9511031D0 (en) *	1995-06-01	1995-07-26	Merck Sharp & Dohme	Chemical process
GB9513118D0 (en) *	1995-06-28	1995-08-30	Merck Sharp & Dohme	Therapeutic agents
GB9513121D0 (en) *	1995-06-28	1995-08-30	Merck Sharp & Dohme	Therapeutic agents
GB9513117D0 (en) *	1995-06-28	1995-08-30	Merck Sharp & Dohme	Therapeutic agents
GB9523244D0 (en) *	1995-11-14	1996-01-17	Merck Sharp & Dohme	Therapeutic agents
ES2147889T3 (es) *	1996-01-19	2000-10-01	Lonza Ag	Metodo para preparar 3-hidroxiquinuclidinol opticamente activo.
GB9603137D0 (en) *	1996-02-15	1996-04-17	Merck Sharp & Dohme	Therapeutic agents
GB9603136D0 (en) *	1996-02-15	1996-04-17	Merck Sharp & Dohme	Therapeutic agents
US6423708B1 (en)	1996-09-30	2002-07-23	Pfizer Inc	Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk)	1996-09-30	2003-05-15	Пфайзер Інк.	Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
JP2001502311A (ja) *	1996-10-07	2001-02-20	メルクシヤープエンドドームリミテツド	抗鬱及び／又は抗不安薬としてのｃｎｓ浸透性ｎｋ―１受容体拮抗薬
US6117855A (en)	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5750549A (en) *	1996-10-15	1998-05-12	Merck & Co., Inc.	Cycloalkyl tachykinin receptor antagonists
DE69732133T2 (de) *	1996-12-02	2005-12-22	Merck Sharp & Dohme Ltd., Hoddesdon	Verwendung von NK-1 Rezeptorantagonisten zur Behandlung von schweren Depressionen
CA2273853A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating cognitive disorders
WO1998024445A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating schizophrenic disorders
CA2273856A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating bipolar disorders
JP2001504849A (ja) *	1996-12-02	2001-04-10	メルクシヤープエンドドームリミテツド	ストレス障害の治療のためのｎｋ−１受容体拮抗薬の使用
CA2273351A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating sexual dysfunction
US6114315A (en) *	1996-12-02	2000-09-05	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
AU731674B2 (en) *	1996-12-02	2001-04-05	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating substance use disorders
AU734872B2 (en) *	1996-12-02	2001-06-21	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating movement disorders
US6100256A (en) *	1996-12-02	2000-08-08	Merck Sharp & Dohme Ltd.	Use of NK-1 receptors antagonists for treating schizophrenic disorders
AU729708B2 (en) *	1996-12-02	2001-02-08	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating severe anxiety disorders
US5977104A (en) *	1996-12-02	1999-11-02	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating bipolar disorders
ATE288756T1 (de) *	1996-12-02	2005-02-15	Merck Sharp & Dohme	Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
US6613765B1 (en)	1996-12-02	2003-09-02	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating major depressive disorders
BR9807056A (pt) *	1997-01-09	2000-05-02	Bifodan As	Uso de álcool diclorobenzìlico, e preparação para tratamento tópico da inflamação
CA2287487A1 (en) *	1997-04-24	1998-10-29	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating eating disorders
ZA985765B (en) *	1997-07-02	1999-08-04	Merck & Co Inc	Polymorphic form of a tachykinin receptor antagonist.
GB9716463D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
WO1999007375A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
CA2298777A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating mania
GB9716457D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
US6156749A (en) *	1997-12-01	2000-12-05	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating movement disorders
US6087348A (en) *	1997-12-01	2000-07-11	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating stress disorders
US6271230B1 (en)	1997-12-01	2001-08-07	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating cognitive disorders
GB9810920D0 (en) *	1998-05-21	1998-07-22	Merck Sharp & Dohme	Therapeutic use
GB9816897D0 (en) *	1998-08-04	1998-09-30	Merck Sharp & Dohme	Therapeutic use
GB9819888D0 (en) *	1998-09-11	1998-11-04	Merck Sharp & Dohme	Chemical synthesis
US6218390B1 (en) *	1998-12-17	2001-04-17	Synaptic Pharmaceutical Corporation	Morpholinone and morpholine derivatives and uses thereof
EP1041070B1 (de) *	1999-03-30	2004-09-22	Pfizer Products Inc.	Verfahren zur Herstellung von cyclischen Thioamiden
MXPA02004330A (es)	1999-11-03	2004-07-30	Albany Molecular Res Inc	Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
DK1103545T3 (da) *	1999-11-29	2004-03-15	Hoffmann La Roche	2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
AU7334901A (en)	2000-07-11	2002-01-21	Du Pont Pharm Co	Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
GB0022988D0 (en) *	2000-09-19	2000-11-01	Merck Sharp & Dohme	Therapeutic agents
DE10116978A1 (de) *	2001-04-05	2002-10-10	Merck Patent Gmbh	Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US6638981B2 (en)	2001-08-17	2003-10-28	Epicept Corporation	Topical compositions and methods for treating pain
KR20050075356A (ko) *	2002-10-11	2005-07-20	싸이토키네틱스, 인코포레이티드	화합물, 조성물 및 방법
WO2005090300A1 (en)	2004-03-17	2005-09-29	Pfizer Products Inc.	Novel benzyl(idene)-lactam derivatives
BRPI0513359A (pt)	2004-07-15	2008-05-06	Amr Technology Inc	tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina
EP1888050B1 (de)	2005-05-17	2012-03-21	Merck Sharp & Dohme Ltd.	Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
UA95454C2 (uk)	2005-07-15	2011-08-10	Амр Текнолоджи, Інк.	Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
EP2083831B1 (de)	2006-09-22	2013-12-25	Merck Sharp & Dohme Corp.	Verfahren zur behandlung von fettsäure-synthese-hemmern
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR064777A1 (es)	2007-01-10	2009-04-22	Inst Di Reserche D Biolog Mole	Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
US20100105688A1 (en)	2007-01-24	2010-04-29	Glaxo Group Limited	Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
US8106086B2 (en)	2007-04-02	2012-01-31	Msd K.K.	Indoledione derivative
WO2008130616A2 (en) *	2007-04-19	2008-10-30	Schering Corporation	Diaryl morpholines as cb1 modulators
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009104080A2 (en)	2008-02-20	2009-08-27	Targia Pharmaceuticals	Cns pharmaceutical compositions and methods of use
CN102014631A (zh)	2008-03-03	2011-04-13	泰格尔医药科技公司	酪氨酸激酶抑制剂
WO2009124756A1 (en) *	2008-04-08	2009-10-15	European Molecular Biology Laboratory (Embl)	Use of aprepitant and derivatives thereof for the treatment of cancer
AR071997A1 (es)	2008-06-04	2010-07-28	Bristol Myers Squibb Co	Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en)	2009-04-01	2014-04-08	Merck Sharp & Dohme Corp.	Inhibitors of AKT activity
CN102638982B (zh)	2009-05-12	2015-07-08	百时美施贵宝公司	(S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
MX2011011901A (es)	2009-05-12	2012-01-20	Albany Molecular Res Inc	Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
EP2429296B1 (de)	2009-05-12	2017-12-27	Albany Molecular Research, Inc.	7-([1,2,4,]triazol[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorphenyl)-1,2,3,4- tetrahydroisochinolin und seine verwendung
AU2010307198B9 (en)	2009-10-14	2014-02-13	Merck Sharp & Dohme Corp.	Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (de)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Neue heterozyklische verbindungen als erk-hemmer
JP6043285B2 (ja)	2010-08-02	2016-12-14	サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
LT2606134T (lt)	2010-08-17	2019-07-25	Sirna Therapeutics, Inc.	Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP2608669B1 (de)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
US8946216B2 (en)	2010-09-01	2015-02-03	Merck Sharp & Dohme Corp.	Indazole derivatives useful as ERK inhibitors
EP2615916B1 (de)	2010-09-16	2017-01-04	Merck Sharp & Dohme Corp.	Kondensierte pyrazolderivate als neue erk-hemmer
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (de)	2010-12-21	2016-07-27	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
EP2699568A1 (de)	2011-04-21	2014-02-26	Piramal Enterprises Limited	Kristalline form eines morpholinsulfonylindolderivat-salzes und verfahren zu seiner herstellung
EP2770987B1 (de)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Neue verbindungen als erk-hemmer
EP3453762B1 (de)	2012-05-02	2021-04-21	Sirna Therapeutics, Inc.	Sina-zusammensetzungen
EP2900241B1 (de)	2012-09-28	2018-08-08	Merck Sharp & Dohme Corp.	Neuartige verbindungen als erk-hemmer
AU2013352568B2 (en)	2012-11-28	2019-09-19	Merck Sharp & Dohme Llc	Compositions and methods for treating cancer
ES2707305T3 (es)	2012-12-20	2019-04-03	Merck Sharp & Dohme	Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en)	2013-01-30	2017-01-10	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (de)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Kreisförmige polynukleotide
WO2018071283A1 (en)	2016-10-12	2018-04-19	Merck Sharp & Dohme Corp.	Kdm5 inhibitors
US11098059B2 (en)	2017-11-08	2021-08-24	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
WO2019094311A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
WO2020033284A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
US11993602B2 (en)	2018-08-07	2024-05-28	Merck Sharp & Dohme Llc	PRMT5 inhibitors
US12173026B2 (en)	2018-08-07	2024-12-24	Merck Sharp & Dohme Llc	PRMT5 inhibitors
IL296635A (en)	2020-04-03	2022-11-01	Nerre Therapeutics Ltd	An nk-1 receptor antagonist for the treatment of a disease selected from sepsis, septic shock, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome (MODS)
KR20230018485A (ko)	2020-06-02	2023-02-07	네르 쎄라퓨틱스 리미티드	폐에 대한 기계적 손상에 의해 촉진된 폐 섬유증 상태의 치료에 사용하기 위한 뉴로키닌 (nk)-1 수용체 길항제
CN115650969B (zh) *	2022-10-29	2024-10-01	河南师范大学	一种α-取代-β-胺氧基取代吗啉类化合物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4476311A (en) *	1980-03-12	1984-10-09	The Purdue Frederick Company	Analgesic 4-carboxy-pyrrolidin-2-one compound
JPS5739599A (en) *	1980-08-20	1982-03-04	Fuji Machine Mfg	Method and device for automatically mounting leadless electronic part on printed board or like
FR2534915B1 (fr) *	1982-10-26	1985-10-25	Lafon Labor	Nouveaux derives de 2-(phenoxymethyl)-morpholine, utilisation en therapeutique et procede de preparation
UA41251C2 (uk) *	1990-01-04	2001-09-17	Пфайзер, Інк.	Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
ATE136885T1 (de) *	1991-08-20	1996-05-15	Merck Sharp & Dohme	Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen

1993
- 1993-06-25 IL IL106142A patent/IL106142A/xx not_active IP Right Cessation
- 1993-06-25 CA CA002099233A patent/CA2099233A1/en not_active Abandoned
- 1993-06-28 MY MYPI93001250A patent/MY108836A/en unknown
- 1993-06-28 MX MX9303888A patent/MX9303888A/es unknown
- 1993-06-28 ZA ZA934624A patent/ZA934624B/xx unknown
- 1993-06-28 HR HR931003 patent/HRP931003B1/xx not_active IP Right Cessation
- 1993-06-29 SI SI9300346A patent/SI9300346B/sl unknown
- 1993-06-29 DE DE69326977T patent/DE69326977T2/de not_active Expired - Lifetime
- 1993-06-29 DZ DZ930080A patent/DZ1700A1/fr active
- 1993-06-29 RU RU94046364A patent/RU2140914C1/ru active
- 1993-06-29 SK SK1600-94A patent/SK281093B6/sk not_active IP Right Cessation
- 1993-06-29 ES ES93305086T patent/ES2141133T3/es not_active Expired - Lifetime
- 1993-06-29 AT AT93305086T patent/ATE186532T1/de active
- 1993-06-29 EP EP93305086A patent/EP0577394B1/de not_active Expired - Lifetime
- 1993-06-29 AU AU46561/93A patent/AU4656193A/en not_active Abandoned
- 1993-06-29 HU HU9403804A patent/HU219713B/hu unknown
- 1993-06-29 CZ CZ19943330A patent/CZ288530B6/cs not_active IP Right Cessation
- 1993-06-29 YU YU45293A patent/YU49036B/sh unknown
- 1993-06-29 JP JP5212045A patent/JP2634372B2/ja not_active Expired - Lifetime
- 1993-06-29 CN CN93109517A patent/CN1049431C/zh not_active Expired - Lifetime
- 1993-06-29 NZ NZ254476A patent/NZ254476A/en not_active IP Right Cessation
- 1993-06-29 KR KR1019940704776A patent/KR100301212B1/ko not_active Expired - Lifetime
- 1993-06-29 RO RO94-02095A patent/RO114448B1/ro unknown
- 1993-06-29 WO PCT/US1993/006181 patent/WO1994000440A1/en not_active Ceased
- 1993-06-29 DK DK93305086T patent/DK0577394T3/da active
- 1993-08-17 TW TW082106583A patent/TW358808B/zh not_active IP Right Cessation
1994
- 1994-12-19 BG BG99274A patent/BG62963B1/bg unknown
- 1994-12-28 NO NO945064A patent/NO305698B1/no not_active IP Right Cessation
- 1994-12-28 FI FI946133A patent/FI111363B/fi not_active IP Right Cessation
1997
- 1997-04-30 BR BR1100375-8A patent/BR1100375A/pt active IP Right Grant
1999
- 1999-11-11 GR GR990402842T patent/GR3031824T3/el unknown
2000
- 2000-09-07 LV LVP-00-118A patent/LV12568B/lv unknown
- 2000-11-02 CY CY0000052A patent/CY2200B1/xx unknown

Also Published As

Publication number	Publication date
ZA934624B (en)	1994-06-20
BG99274A (bg)	1996-04-30
RO114448B1 (ro)	1999-04-30
SK281093B6 (sk)	2000-11-07
HK1009268A1 (en)	1999-05-28
YU45293A (sh)	1996-10-18
SK160094A3 (en)	1995-07-11
SI9300346A (sl)	1993-12-31
KR100301212B1 (ko)	2001-10-22
RU94046364A (ru)	1996-10-10
YU49036B (sh)	2003-07-07
SI9300346B (sl)	2003-10-31
AU663595B2 (en)	1995-10-12
BG62963B1 (bg)	2000-12-29
NO945064L (no)	1995-02-28
NZ254476A (en)	1996-09-25
AU4656193A (en)	1994-01-24
NO945064D0 (no)	1994-12-28
DZ1700A1 (fr)	2002-02-17
ES2141133T3 (es)	2000-03-16
LV12568A (en)	2000-11-20
FI111363B (fi)	2003-07-15
DE69326977D1 (de)	1999-12-16
HU9403804D0 (en)	1995-02-28
HU219713B (hu)	2001-06-28
BR1100375A (pt)	2000-03-14
HUT71809A (en)	1996-02-28
RU2140914C1 (ru)	1999-11-10
CY2200B1 (en)	2002-11-08
WO1994000440A1 (en)	1994-01-06
EP0577394A1 (de)	1994-01-05
HRP931003A2 (en)	1995-02-28
NO305698B1 (no)	1999-07-12
CN1049431C (zh)	2000-02-16
MY108836A (en)	1996-11-30
CZ333094A3 (en)	1995-09-13
JP2634372B2 (ja)	1997-07-23
AU4156893A (en)	1994-01-06
FI946133A0 (fi)	1994-12-28
MX9303888A (es)	1994-03-31
TW358808B (en)	1999-05-21
KR950702193A (ko)	1995-06-19
CZ288530B6 (cs)	2001-07-11
CN1087902A (zh)	1994-06-15
FI946133L (fi)	1994-12-28
DE69326977T2 (de)	2000-06-08
EP0577394B1 (de)	1999-11-10
ATE186532T1 (de)	1999-11-15
LV12568B (lv)	2001-04-20
DK0577394T3 (da)	2000-03-27
HRP931003B1 (en)	2000-10-31
IL106142A0 (en)	1993-10-20
CA2099233A1 (en)	1993-12-30
GR3031824T3 (en)	2000-02-29
JPH06172178A (ja)	1994-06-21

Legal Events

Date	Code	Title
1997-09-30	FF	Patent granted
1998-02-08	KB	Patent renewed
1999-12-22	KB	Patent renewed
2003-07-31	KB	Patent renewed
2007-03-08	EXTF	Application for patent extension filed
2007-07-24	KB	Patent renewed
2011-06-30	KB	Patent renewed
2014-01-30	EXP	Patent expired

Publication	Publication Date	Title
IL106142A (en)	1997-03-18	Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
YU49037B (sh)	2003-07-07	Morfolin antagonisti receptora tahikinina
ES2272820T3 (es)	2007-05-01	Bifenilmetilo-tiazolidinadionas y analagos y su utilizacion como activador ppar-gamma.
CA2674237C (en)	2015-11-24	N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
US7053057B2 (en)	2006-05-30	Caspase inhibitors and uses thereof
US7122564B2 (en)	2006-10-17	Biaromatic ligand activators of PPARγ receptors
DE69223574D1 (de)	1998-01-29	Durch eine Amide-Gruppe substituierte Spiroindanylcamphorsulfonylderivate als Oxytocin-Antagonisten
US20040039038A1 (en)	2004-02-26	Biaromatic compound activators of PPARy-type receptors
IL97018A0 (en)	1992-03-29	N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2h-benzopyran)carboxamide derivatives,their preparation and pharmaceutical compositions containing them
OA11577A (en)	2004-07-26	Non-peptidyl inhibitors of VLA-4 dependent cell vinding useful in treating inflammatory, autoimmune,and respiratory diseases.
US20010007870A1 (en)	2001-07-12	Compounds useful for inhibition of farnesyl protein transferase
MY117803A (en)	2004-08-30	Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
IL127942A0 (en)	1999-11-30	1,4-Di-substituted piperidines as muscarinic antagonists
CA2505299C (en)	2012-11-13	Novel biaromatic compunds which activate ppary type receptors, and use therof in cosmetic or pharmaceutical compositions
AU2005283326A1 (en)	2006-03-23	Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
RO117846B1 (ro)	2002-08-30	Derivaţi ai acidului acetic, procedeu de preparare a acestora, compoziţie farmaceutică care îi conţine şi metodă de tratament
MXPA03010584A (es)	2004-03-09	Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas.
JP2023533203A (ja)	2023-08-02	セレブロン結合化合物、その組成物及びそれによる治療方法
NZ334377A (en)	2000-11-24	use of ketone substituted indanone derivatives for treating cell proliferation disorders and compositions thereof
RU2006120488A (ru)	2008-01-10	НОВЫЕ ИНГИБИТОРЫ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ ТИПА I
CN115968293A (zh)	2023-04-14	Cereblon结合化合物、其组合物及其用于治疗的方法
AR006518A1 (es)	1999-09-08	Esteres de derivados de 1,4-piperidina disustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y un procedimiento para su preparacion
MY129176A (en)	2007-03-30	Tetrahydro gamma-carbolines
NO944069L (no)	1995-05-02	Hemming av uterinfibrose
TW200616636A (en)	2006-06-01	Novel compounds